Navigation Links
Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
Date:7/29/2008

WASHINGTON DC, July 29 /PRNewswire/ -- Athera Biotechnology announced the Award from NACB (National Academy of Clinical Biochemistry) for Distinguished Abstracts at the annual AACC (American Association of Clinical Chemistry) meeting in Washinton DC was awarded to Athera Biotechnology founder Johan Frostegard and his colleagues. The abstract was one of 26 selected for the award, among over 700 accepted abstracts. Winners will be honored at NACB Award luncheon held at the AACC meeting on July 30.

Frostegard's abstract describes a study where low levels of antibodies against phosphorylcholine (anti-PC) were measured using an enzyme linked immunoassay (ELISA) by CVDefine(TM), a new kit developed by Athera. The findings indicate that low levels of IgM anti-PC are associated with an increased risk of cardiovascular disease (CVD) in a population. Frostegard and colleagues conclude that low levels of anti-PC could be a novel risk marker for CVD and ischemic stroke, especially in men.

Athera Biotechnologies AB develops novel products for risk assessment and treatment of CVD. The company was founded in 2002 to exploit findings made by Professors Johan Frostegard and Ulf de Faire on the critical role of phospholipid antibodies (aPL) in the inflammatory process of cardiovascular disease. Athera is based in Karolinska Institutet Science Park in Stockholm and main investors include Karolinska Development and Baltic Sea Foundation. Athera is also a major partner in the highly ranked EU-project CVDIMMUNE lead by Karolinska Institutet. The project involves 10 academic and industrial partners, including Phadia GmbH, Johannes Gutenberg-University Mainz and Leiden University Medical Center.


'/>"/>
SOURCE Athera Biotechnologies AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study
2. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
3. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
4. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
5. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
6. N.C. Biotechnology Center Launches Industrial Fellowship Program
7. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
8. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
9. Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
10. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Spain , Dec. 8, 2016  Anaconda BioMed ... the development of the next generation neuro-thrombectomy system for ... appointment of Tudor G. Jovin, MD to join its ... serve as a strategic network of scientific and clinical ... the development of the ANCD BRAIN ® to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016   SoftServe , a global digital ... an electrocardiogram (ECG) biosensor analysis system for continuous ... asset. The smart system ensures device-to-device communication between ... and mobile devices to easily ,recognize, and monitor ... vehicle technology advances, so too must the security ...
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
(Date:11/28/2016)... , Nov. 28, 2016 ... a rate of 16.79%" The biometric system market ... grow further in the near future. The biometric system ... billion in 2022, at a CAGR of 16.79% between ... system, integration of biometric technology in smartphones, rising use ...
Breaking Biology News(10 mins):